XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation
Preclinical data demonstrate subnanomolar silencing potency, achieving an IC50 tens of times lower than the corresponding values for two clinical-stage reference molecules targeting the same target. In non-human primates, a single dose maintained robust target-protein suppression for...
Covered in this story
Call it yourself
No calls on $NINE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Nine Energy Service →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.